Biote Corp. — Earnings Quality Grade F
BTMD · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 13 days, change -1 days YoY
AR growth -10.0% vs revenue growth -2.5%
Revenue -2.5%, CFFO -22.2%. Cash follows revenue
Expense Quality
Inventory growth 28.4% exceeds COGS -5.6%
CapEx growth -1.3% vs revenue -2.5%. Normal
SG&A/Gross Profit = 74.1%, exceeds 70%
Gross margin 71.5%, change +0.9pp. Stable
Cash Flow Quality
CFFO/NI = 1.30. Profits backed by cash
FCF $0.0B, FCF/NI = 1.05
Accruals ratio = -7.6%. Low accruals
Cash $0.0B covers only 22% of debt $0.1B
Balance Sheet Health
Goodwill+Intangibles $0.0B = -25% of equity. Manageable
Debt/EBITDA = 2.1x. Healthy
Other assets 0.0% vs revenue -2.5%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -4% YoY. Normal
Manipulation Score
M-Score = -2.93 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor BTMD continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25